6 hrs ago | Philly.com
NRC cites VA clinic for radioactive-treatment violations
In the first outside report on its flawed prostate-cancer program, the Philadelphia VA Medical Center was cited for eight apparent violations in using radioactive materials on nearly 100 veterans, federal inspectors have concluded.
Dendreon's Provenge gets FDA review date
Biotechnology company Dendreon said Friday that the Food and Drug Administration will make a regulatory decision on the potential prostate... Biotechnology company Dendreon said Friday that the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1. The drug is aimed at treating ...
Discovery Boosts Boys' Prospects for Post-Cancer Fertility
New research suggests it may become possible for pre-pubescent boys stricken by cancer to prepare for the future when they may be infertile but still want to become natural fathers.
Dendreon Receives FDA Acknowledgement of Complete Response- PDUFA Date Assigned as May 1, 2010
Dendreon Corporation today announced that the FDA provided written acknowledgement that the Company's amended Biologics License Application for PROVENGE is a complete response.
Multidisciplinary Meeting On Urological Cancers
Experts agree that the urological cancer patient will benefit greatly if the delivered treatment is the result of a combined effort.
Prostate Cancer Surgery Performed by Many Surgeons with Little Experience
A new study from researchers at Memorial Sloan-Kettering Cancer Center has found that the majority of surgeons treating prostate cancer in the United States have extremely low annual caseloads, potentially leading to increased rates of both surgical complications and cancer recurrence.
Test helps determine prostate cancer treatment
Bay Area researchers are using a new test to help determine whether a patient should be treated for prostate cancer.
Abnormal mammogram: understanding false-positives An abnormal mammogram result can be scary, but in many cases it's a false alarm.
Healthy strategies: Prostate screenings
In light of recent reports raising new questions about prostate screenings and treatments, I decided to share again some basic information that may be found to be helpful.
Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented
Synta Pharmaceuticals Corp. , a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of ...
Drug may tackle prostate cancer
Men with advanced prostate cancer could be treated by new drugs being tested in Belfast.
Cancer-stricken Webber back in hospital
Sir Andrew Lloyd Webber poses in front of the winners' boards with the award for Outstanding Achievement in Music at the Classical Brit Awards 2008 at the Royal Albert Hall on May 8, 2008 in London, England.
Ex-Kiss drummer Peter Criss, a survivor of male breast cancer, urges men to get checked for it
Lying in bed one night in 2007, Peter Criss felt something strange: a small lump on his left breast.
New breast cancer guidelines highlight health care split
On one side are women's health organizations, doctors and breast cancer survivors who stand by the status quo - annual mammograms starting at age 40.
Robotic Prostatectomy Expert Dr. David Samadi Clarifies American...
In the article, Dr. Otis Brawley, chief medical officer of the ACS, responded to a study in the current issue of the Journal of the American Medical Association.
IsoRay Inc. Reports First Quarter Results
IsoRay Inc. a medical isotope company focusing on the treatment of prostate, lung, head and neck and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the first quarter of fiscal year 2010, ended September 30, 2009.
Health groups $1 tax hike on cigarettes
Former state Senate President Pro Tem and 2010 Oakland mayoral candidate Don Perata joined cancer research and health advocates Monday to launch a ballot measure that would hike cigarette taxes by a dollar a pack.
Watchful waiting for prostate cancer is safe: study
Taking a watch and wait approach to prostate cancer, rather than attempting to remove the cancer, is a safe approach and doesn't lead to more deaths, concludes a new analysis.
Degarelix: A New Approach For The Treatment Of Prostate Cancer
Main Category: Prostate / Prostate Cancer Also Included In: Urology / Nephrology ; Cancer / Oncology Article Date: 16 Nov 2009 - 4:00 PST UroToday.com - Gonadotrophin-releasing hormone agonists are currently the 'standard of care' for androgen deprivation therapy in prostate cancer .
Androgen receptor as a licensing factor for DNA replication in...
Besides its ability to function as a transcription factor, experimental observations suggest that AR becomes a licensing factor for DNA replication in AS prostate cancer cells and thus must be degraded during each cell cycle in these cells to allow reinitiation of DNA replication in the next cell cycle.
Also on Topix